Piśmiennictwo

1. Reichlin T. High sensitivity troponin assays in the diagnosis of ACS patients. Application to differential diagnosis. ProCardio Symposium, 8 International Symposium on Cardiac Biomarkers, August 25-26, 2011, Paris, France.

2. Bergmann O, Bhardwaj R, Bernard S. Evidence for cardiomyocyte renewal in humans. Science 2009; 324: 98-102.

3. White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? JACC 2011; 57: 2406-2408.

4. Melki D, Lind S, Agewall S, et al. Diagnostic value of high sensitive troponin T in chest pain patients with no persistent ST-elevations. Scand Cardiovasc J 2011; 45: 198-204.

5. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; doi:10.1093/eurheartj/ehr236.

6. Giannitsis E, Katus H. Current recommendations for interpretation of the highly sensitive troponin T assay for diagnostic, therapeutic and prognostic purposes in patients with a non-ST-segment-elevation acute coronary syndrome. Eur Cardiol 2010; 5: 44-47.

7. Giannitsis E. High sensitive troponin assays in the diagnosis of ACS patients. Implementation in everyday practice. ProCardio Symposium, 8 International Symposium on Cardiac Biomarkers, August 25-26, 2011, Paris, France.

8. White HD. Role of the high sensitive Troponin assays in the universal Definition of AMI. The cardiologist’s perspective. ProCardio Symposium, 8 International Symposium on Cardiac Biomarkers, August 25-26, 2011, Paris, France.

9. Morrow D, Cannon C, Jesse R, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007; 53: 552-574.

10. Reichlin T, Irfan A, Twerenbold R. Utility of absolute and relative changes in cardiac troponin concentration in the early diagnosis of acute myocardial infarction. Circulation, 2011; 124: 136-145.

11. Agewall S, Giannitsis E, Jernberg T, et al. Troponin elevation in coronary vs. non-coronary disease. Eur Heart J 2011; 32: 404-411.

12. Giannitis E, Katus HA. Clinical case studies and result interpretation Elecsyc® cardiac troponin T-high sensitive test. Roche, 2011.

13. Ray P. Role of the high sensitive Troponin assays in the universal Definition of AMI. The emergency doctor’s perspective. ProCardio Symposium, 8 International Symposium on Cardiac Biomarkers, August 25-26, 2011, Paris, France.

14. Katus HA. The value of the Troponin T-high sensitive assay in risk stratification and prognosis. In patients with acute chest pain. ProCardio Symposium, 8 International Symposium on Cardiac Biomarkers, August 25-26, 2011, Paris, France.

15. Omland T. The value of the Troponin T-high sensitive assay in risk stratification and prognosis. In patients with ACS and stable CAD. ProCardio Symposium, 8 International Symposium on Cardiac Biomarkers, August 25-26, 2011, Paris, France.

16. Ndrepepa G, Braun S, Schulz S, et al. High-sensitivity troponin T level and angiographic severity of coronary artery disease. Am J Cardiol 2011; 108: 639-643.

17. Korosoglou G, Lehrke S, Mueller D, et al. Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. Heart 2011; 97: 823-831.

18. Masson S, Latini R, Anand I. An update on cardiac troponins as circulating biomarkers in heart failure. Curr Heart Fail Rep 2010; 7: 15-21.

19. McGill D, Talaulikar G, Potter J, et al. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. Clin Chim Acta 2010; 411: 936-439.

20. deFilippi C. The value of the Troponin T-high sensitive assay in risk stratification and prognosis in community-based populations from the USA. ProCardio Symposium, 8 International Symposium on Cardiac Biomarkers, August 25-26, 2011, Paris, France.

21. Hildebrandt P, Collinson P, Doughty R, et al. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur Heart J 2010; 31: 1881-1889.

22. Berger R. Best practice: Guided heart failure therapy using NT-proBNP. NT-proBNP guided therapy plus multidisciplinary care. ProCardio Symposium, 8 International Symposium on Cardiac Biomarkers, August 25-26, 2011, Paris, France.

23. Januzzi J. Insights from the PROTECT study. Primary results, quality of life, mechanistic correlates and lack of age interaction with therapy. ProCardio Symposium, 8 International Symposium on Cardiac Biomarkers, August 25-26, 2011, Paris, France.

24. Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. JACC 2011; 58:1881-1889.

25. Jourdain P: Best practice: Guided heart failure therapy using NT-proBNP. Existing trials and open questions in HF therapy monitoring. ProCardio Symposium, 8 International Symposium on Cardiac Biomarkers, August 25-26, 2011, Paris, France.

26. Richards M (Singapore). New horizon on biomarkers. Update on emerging cardiac markers. ProCardio Symposium, 8 International Symposium on Cardiac Biomarkers, August 25-26, 2011, Paris, France.

27. Kempf T, Horn-Wichmann R, Brabant G, et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 2007; 53: 284-291.

28. Bonaca M, Morrow D, Braunwald E, et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscl Throm Vas 2011; 31: 203-210.

29. Anand I, Kempf T, Rector T, et al. Serial measurement of growth-differentiation factor-15 in heart failure. Relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010; 122: 1387-1395.

30. Weinberg E, Shimpo M, De Keulenaer G, et. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106: 2961-2966.

31. Rehman,S, Mueller T, Januzzi J, et al. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. JACC 2008; 52: 1458-1465.

32. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011; 4: 180-187.

33. Januzzi J, Piña L. Optimizing medical management with biomarker-guided care. Interview. ESC Scientific Congress. 27-31 August, 2011, Paris, France.

34. Shah R, Chen-Tournoux A, Picard M, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010; 12: 826-832.

35. de Boer R, Lok D, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43: 60-68.

36. Maisel A, Mueller C, Nowak R, et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. JACC 2011; 58: 1057-1067.

37. Nowak R: Mid-region prohormone adrenomedullin (MR-proADM) identifies acutely dyspneic ED patients with high 90 day mortality: results from the Biomarkers in Acute Heart Failure (BACH) Trial. ESC Scientific Congress. 27-31 August, 2011, Paris, France.

38. Fichtlscherer S, Zeiher A, Dimmeler S. Circulating microRNAs biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol 2011; 31: 2383-2390.

39. Tijsen A, Creemers E, Moerland P, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035-1039.

40. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. NEJM 2008; 358: 2107-2116.